[ad_1]
Final clinical trials for a coronavirus vaccine, developed by AstraZeneca and the University of Oxford, were suspended after a participant had an adverse reaction in the UK.
There were high hopes that the vaccine could be one of the first to hit the market after the successful trials of phases 1 and 2.
In Phase 3 testing, approximately 30,000 participants are involved in the United States, as well as the United Kingdom, Brazil, and South Africa.
But after one of the test participants in the UK fell ill, tests were discontinued in all countries. Meanwhile, an independent investigation has been launched, examining safety data before regulators decide whether the process can be resumed, writes BBC News.
“In large studies, these random diseases will always occur, but they must be controlled independently before proceeding,” said a spokesman for the University of Oxford.
This is the second time that Oxford’s coronavirus vaccine testing process has been suspended.
The testing process is expected to resume in a few days.
The World Health Organization (WHO) says nearly 180 vaccines are being tested worldwide, but none have completed clinical trials.
Edited by Georgiana Marina
